NCT00782184
Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)
See it on ClinicalTrials.gov ↗250 people
48.8%
51.2%
122 womenmiddle line = equal numbers128 men
- Phase
- PHASE3
- Paid for by
- Organon and Co
- Finished
- 2010-09
- Health conditions
- Hypercholesterolemia
- Who could join
- Anyone
- Ages
- 18 Years – 79 Years
- Average age
- mean 59.3 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No pregnant women
Women who were pregnant could not join.
“Females who are pregnant or breastfeeding”
- No breastfeeding moms
Women who were breastfeeding could not join.
“Females who are pregnant or breastfeeding”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Participant has congestive heart failure (New York Heart Association \[NYHA\] Type III or IV)”
- No diabetes
Women with diabetes were turned away.
“Participant is newly diagnosed with type 1 or 2 diabetes”
Study titles and rules are shown in their original English.